Patents by Inventor Robert T. Peters

Robert T. Peters has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMMUNOGLOBULIN CHIMERIC MONOMER-DIMER HYBRIDS
    Publication number: 20170266309
    Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.
    Type: Application
    Filed: March 21, 2017
    Publication date: September 21, 2017
    Applicant: Bioverativ Therapeutics Inc.
    Inventors: Robert T. PETERS, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitonti, Susan C. Low
  • Systems for Factor VIII Processing and Methods Thereof
    Publication number: 20170267744
    Abstract: The present invention provides methods of reducing nonprocessed Factor VIII or a chimeric polypeptide comprising Factor VIII comprising co-transfecting in a host cell a polynucleotide encoding Factor VIII with a polynucleotide encoding a protein convertase, where the endogenous processing enzymes of the host cell are insufficient to convert all of the Factor VIII to its processed isoform; expressing a proprotein convertase from a second polynucleotide in the host cell; and reducing the nonprocessed Factor VIII by processing with said proprotein convertase.
    Type: Application
    Filed: February 22, 2017
    Publication date: September 21, 2017
    Inventors: Susan C. LOW, Robert T. PETERS
  • OPTIMIZED FACTOR IX GENE
    Publication number: 20170260516
    Abstract: The present invention provides codon optimized Factor IX sequences, vectors and host cells comprising codon optimized Factor IX sequences, polypeptides encoded by codon optimized Factor IX sequences, and methods of producing such polypeptides. The present invention also provides methods of treating bleeding disorders such as hemophilia comprising administering to the subject a codon optimized Factor IX nucleic acid sequence or the polypeptide encoded thereby.
    Type: Application
    Filed: June 30, 2015
    Publication date: September 14, 2017
    Applicant: Biogen MA Inc.
    Inventors: Siyuan TAN, Robert T. PETERS, Tongyao LIU
  • IMMUNOGLOBULIN CHIMERIC MONOMER-DIMER HYBRIDS
    Publication number: 20170226189
    Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.
    Type: Application
    Filed: April 19, 2017
    Publication date: August 10, 2017
    Inventors: Robert T. PETERS, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitoni, Susan C. Low
  • Immunoglobulin chimeric monomer-dimer hybrids
    Patent number: 9725496
    Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: August 8, 2017
    Assignee: Bioverative Therapeutics Inc.
    Inventors: Robert T. Peters, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitonti, Susan C. Low
  • Factor IX polypeptides and methods of use thereof
    Patent number: 9675676
    Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: June 13, 2017
    Assignee: BIOVERATIV THERAPEUTICS INC.
    Inventors: Glenn Pierce, Samantha Truex, Robert T. Peters, Haiyan Jiang
  • Factor IX polypeptides and methods of use thereof
    Patent number: 9670475
    Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Grant
    Filed: July 11, 2011
    Date of Patent: June 6, 2017
    Assignee: Bioverativ Therapeutics Inc.
    Inventors: Glenn Pierce, Samantha Truex, Robert T. Peters, Haiyan Jiang
  • Immunoglobulin chimeric monomer-dimer hybrids
    Patent number: 9636416
    Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.
    Type: Grant
    Filed: October 31, 2014
    Date of Patent: May 2, 2017
    Assignee: Bioverativ Therapeutics Inc.
    Inventors: Robert T. Peters, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitoni, Susan C. Low
  • Factor IX polypeptides and methods of use thereof
    Patent number: 9629903
    Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: April 25, 2017
    Assignee: BIOVERATIV THERAPEUTICS INC.
    Inventors: Glenn Pierce, Samantha Truex, Robert T. Peters, Haiyan Jiang
  • Factor IX polypeptides and methods of use thereof
    Patent number: 9623091
    Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: April 18, 2017
    Assignee: BIOVERATIV THERAPEUTICS INC.
    Inventors: Glenn Pierce, Samantha Truex, Robert T. Peters, Haiyan Jiang
  • Systems for factor VIII processing and methods thereof
    Patent number: 9611310
    Abstract: The present invention provides methods of reducing nonprocessed Factor VIII or a chimeric polypeptide comprising Factor VIII comprising co-transfecting in a host cell a polynucleotide encoding Factor VIII with a polynucleotide encoding a protein convertase, where the endogenous processing enzymes of the host cell are insufficient to convert all of the Factor VIII to its processed isoform; expressing a proprotein convertase from a second polynucleotide in the host cell; and reducing the nonprocessed Factor VIII by processing with said proprotein convertase.
    Type: Grant
    Filed: July 11, 2011
    Date of Patent: April 4, 2017
    Assignee: Bioverativ Therapeutics Inc.
    Inventors: Susan C. Low, Robert T. Peters
  • Factor IX Polypeptides and Methods of Use Thereof
    Publication number: 20160346365
    Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Application
    Filed: February 12, 2016
    Publication date: December 1, 2016
    Applicant: Biogen Hemophilia Inc.
    Inventors: Glenn PIERCE, Samantha Truex, Robert T. Peters, Haiyan Jiang
  • CHARACTERIZATION OF PRE-REFINED CRUDE DISTILLATE FRACTIONS
    Publication number: 20160319208
    Abstract: Methods are provided for qualifying jet fuel fractions that are derived at least in part from pre-refined crude oil sources. The methods allow for determination of the stability of a jet fuel product over time by using an accelerated aging test. The methods are beneficial for verifying the stability of a jet fuel fraction that includes a portion derived from a pre-refined crude oil.
    Type: Application
    Filed: June 14, 2016
    Publication date: November 3, 2016
    Inventors: Roger G. GAUGHAN, Robert T. PETERS, Timothy D. SUTER, Bryan M. KNICKERBOCKER
  • RECOMBINANT FACTOR VIII PROTEINS
    Publication number: 20160311885
    Abstract: Provided are recombinant Factor VIII proteins, e.g., human Factor VIII proteins, in which one or more amino acids in at least one permissive loops or a3 domain are substituted or deleted, or replaced with heterologous moieties, while retaining the procoagulant activity of Factor VIII.
    Type: Application
    Filed: August 14, 2014
    Publication date: October 27, 2016
    Applicant: Biogen MA Inc.
    Inventors: Robert T. Peters, John Kulman
  • Factor IX Polypeptides and Methods of Use Thereof
    Publication number: 20160257943
    Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Application
    Filed: December 29, 2015
    Publication date: September 8, 2016
    Inventors: Glenn Pierce, Samantha Truex, Robert T. Peters, Haiyan Jiang
  • Factor IX Polypeptides and Methods of Use Thereof
    Publication number: 20160243206
    Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Application
    Filed: February 12, 2016
    Publication date: August 25, 2016
    Applicant: Biogen Hemophilia Inc.
    Inventors: Glenn PIERCE, Samantha Truex, Robert T. Peters, Haiyan Jiang
  • Characterization of pre-refined crude distillate fractions
    Patent number: 9394497
    Abstract: Methods are provided for qualifying jet fuel fractions that are derived at least in part from pre-refined crude oil sources. The methods allow for determination of the stability of a jet fuel product over time by using an accelerated aging test. The methods are beneficial for verifying the stability of a jet fuel fraction that includes a portion derived from a pre-refined crude oil.
    Type: Grant
    Filed: September 9, 2013
    Date of Patent: July 19, 2016
    Assignee: EXXONMOBIL RESEARCH AND ENGINEERING COMPANY
    Inventors: Roger G. Gaughan, Robert T. Peters, Timothy D. Suter, Bryan M. Knickerbocker
  • FACTOR VIII-XTEN FUSIONS AND USES THEREOF
    Publication number: 20160199454
    Abstract: The present invention provides chimeric proteins comprising a Factor VIII (FVIII) polypeptide and XTEN polypeptides. The FVIII polypeptide can have a reduced affinity for von Willebrand Factor (VWF). XTEN polypeptides of appropriate sizes are inserted into the FVIII polypeptide at particular locations in order to extend the half-life of the FVIII polypeptide. The invention also includes nucleotides, vectors, host cells, and methods of using the chimeric proteins, e.g., to treat bleeding diseases and disorders.
    Type: Application
    Filed: August 14, 2014
    Publication date: July 14, 2016
    Applicants: Biogen MA Inc., Amunix Operating Inc.
    Inventors: Tongyao LIU, Pei-Yun CHANG, John KULMAN, Volker SCHELLENBERGER, Haiyan JIANG, Robert T. PETERS, Ekta Seth CHHABRA
  • Factor IX Polypeptides and Methods of Use Thereof
    Publication number: 20160166657
    Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Application
    Filed: February 12, 2016
    Publication date: June 16, 2016
    Applicant: Biogen Hemophilia Inc.
    Inventors: Glenn PIERCE, Samantha Truex, Robert T. Peters, Haiyan Jiang
  • Factor IX polypeptides and methods of use thereof
    Patent number: 9233145
    Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: January 12, 2016
    Assignee: Biogen Hemophila Inc.
    Inventors: Glenn Pierce, Samantha Truex, Robert T. Peters, Haiyan Jiang